Mirabegron Tablet 25mg, 50mg Suppliers & Bulk Manufacturers

Available Forms: Tablet

Available Strengths: 25mg, 50mg

Reference Brands: Myrbetriq (USA), Betmiga (EU/UK), Mirago (India)

Category: Urology

Mirabegron is a beta-3 adrenergic receptor agonist used for the treatment of overactive bladder (OAB), a condition characterized by symptoms such as urinary urgency, increased frequency, and urge incontinence. It works by relaxing the detrusor smooth muscle of the bladder, allowing it to store more urine and reduce the urge to urinate frequently.

Product Description:

Mirabegron is a sympathomimetic agent indicated for the management of overactive bladder (OAB) with symptoms of urge urinary incontinence, urinary urgency, and increased urinary frequency. It was approved by the United States Food and Drug Administration (FDA) in June 2012 as a novel therapeutic option for patients who require an alternative to antimuscarinic therapy. Mirabegron acts as a selective beta-3 adrenergic receptor agonist, stimulating receptors in the detrusor muscle of the bladder. This action promotes relaxation of the bladder during the storage phase of the micturition cycle, thereby increasing bladder capacity and reducing involuntary contractions.

Mirabegron is generally administered as an extended-release oral tablet and is designed for once-daily dosing. It is particularly useful in patients who cannot tolerate anticholinergic adverse effects such as dry mouth or constipation. The medication is metabolized primarily in the liver and requires dose considerations in patients with severe renal or hepatic impairment. Common adverse effects may include hypertension, nasopharyngitis, urinary tract infection, and headache. Careful monitoring is recommended in patients with uncontrolled hypertension or those taking interacting medications.